Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
A composition comprising erythropoietin (EPO) or an active fragment or analogue thereof and mesenchymal stem cells (MSCs) is provided for the treatment of motor neuron diseases (MND), especially amyotrophic lateral sclerosis (ALS). Also, provided is a method for the treatment of motor neuron diseases by which erythropoietin (EPO) or an active fragment or analogue thereof and mesenchymal stem cells (MSCs) are administered simultaneously or sequentially.
The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM) -derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to the site of an injury such as injuries associated with osteointegration of implants and associated soft tissues, fat grafting and endochondral bone injuries and disease.
We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.
Method for the detection of cancerous cells, in particular, mesenchymal tumoral cells, in a biological sample suspected of containing said malignant cells. The methods are based on the aberrant expression of the Slug gene or transcription or expression products thereof. Also disclosed are methods of treatment that based on the alteration of the transcription or expression of the Slug gene and methods for screening the compounds that have cancer treating activities. Pharmaceutical compositions comprising the anti-cancer compounds are also disclosed.
An adjuvant for cancer immunotherapy with an immunoactivating agent, which comprises a colony stimulating factor as an active ingredient, can remarkably increase the antitumor effect of said immunoactivating agent.
H: r\)mjeir oveIRPoifbDCCAAR%IhI4R30. .doc-I M/)2/2014 -61 The present inventors revealed the following for the first time in the world: 1) a large amount of bone marrow-derived cells are mobilized to grafted skin; 2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells; 3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin; 4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow; 5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart; 6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and 7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.